NextFin News - Shell has drawn interest from ExxonMobil and LyondellBasell for its US chemical assets in a sale that could raise as much as $8 billion, according to people familiar with the matter, marking the most concrete sign yet that the Anglo-Dutch oil major is prepared to exit a business it no longer believes it should own.
The interest, reported this week, comes roughly 18 months after Shell began a strategic review of its chemicals operations with advisers at Morgan Stanley and after Chief Executive Wael Sawan told investors the company is "not the natural owner" of the portfolio. The potential transaction would be the largest single divestment in Shell's chemicals retreat, a multi-year effort to shrink capital employed in a division that has lost money for three consecutive years.
Shell's chemicals segment generated $9.6 billion in sales in 2024, flat with the prior year, and posted a $392 million loss - an improvement on the $717 million loss recorded in 2023, but a loss nonetheless. Volume grew 6 percent to 11.9 million metric tons, driven by a ramp-up at the company's Monaca polymers complex in Pennsylvania. The divergence - more volume, still losing money - is the crux of Shell's problem and the opportunity for any buyer.
The assets under discussion include Shell's 1,500-acre Deer Park complex in Texas, chemical sites at Geismar and Norco in Louisiana, and the Shell Polymers Monaca plant in Pennsylvania, which alone carried $14 billion of capital employed in 2024. Shell also holds chemical operations in the United Kingdom, Germany and the Netherlands, and runs a joint operation with ExxonMobil at Mossmoran in Scotland.
Market Reaction: Muted Moves, Big Stakes
Shares of Shell closed at $93.33 on the New York Stock Exchange, down 0.34 percent on the day - a fraction of a move that suggests investors have largely priced in a chemicals exit. ExxonMobil slipped 0.63 percent to $165.11 and LyondellBasell fell 0.84 percent to $67.53. The modest price action is consistent with a process that remains early-stage: Shell has not committed to a sale, no bids have been formally received, and an $8 billion valuation is an internal expectation rather than a market-tested number.
That $8 billion figure deserves scrutiny. Shell's entire chemicals division produced $9.6 billion of revenue last year. A price near $8 billion for the US assets alone would imply a multiple close to one times sales for businesses that are currently loss-making - a generous outcome for a seller, and a sign that the real negotiation will be over which assets change hands and on what earn-out or deferred terms.
Why Shell Wants Out: Scale, Not Just the Cycle
The most common reading of Shell's chemicals retreat is that it is a cyclical call - get out while margins are depressed, before a rebound. That reading is too simple, and it mistakes timing for motive. Shell's own explanation points to structure.
At a capital markets briefing in New York in March 2025, Sawan laid out the logic plainly:
We believe we have good, individual [chemical] assets that are well run by a great team, and that there are parts of our portfolio that also possess competitive advantages. However, given our starting point and in particular our lack of scale in some areas, combined with competing opportunities across the group for capital, we do not believe we are the natural owners of this chemicals portfolio.
Three distinct claims sit inside that sentence, and each is structural rather than cyclical. First, "lack of scale" - Shell's US ethylene capacity of 3.82 million metric tons a year is meaningful, but it is not large enough to set the market or to absorb the fixed costs of a full cracker-to-derivatives chain the way Dow or LyondellBasell can. Second, "competing opportunities across the group for capital" - Shell's upstream portfolio, particularly its deepwater and liquefied natural gas positions, offers returns that the chemicals division has not matched. Third, and most important, "not the natural owners" - a statement about ownership suitability, not market timing. A cyclical trader sells because the price will recover; Shell is selling because it believes someone else should own these assets at any price.
Shell's Chief Financial Officer, Sinead Gorman, drew the regional distinction sharply in the same briefing, calling Europe "a really challenged market" and explaining the 2030 timeline for the US by noting that "the market is fundamentally great, longer term. But short term it's pretty challenged." That framing matters: Europe is a structural exit under margin pressure; the US is a structural exit despite a favorable long-term feedstock position. Monaca sits on advantaged Marcellus and Utica shale ethane, yet Shell still considers it for divestment or partnership. If even the best-feedstock asset in North America is not worth keeping, the thesis is about portfolio construction, not commodity prices.
What $8 Billion Buys
A buyer of Shell's US chemicals assets would acquire an integrated Gulf Coast and Appalachian footprint with real competitive attributes. Deer Park produces light and heavy olefins used in pharmaceuticals, adhesives, detergents and wire coating, adjacent to a refinery Shell already sold to Mexico's Pemex for $596 million plus inventory in 2021. Geismar and Norco in Louisiana sit in the heart of the US petrochemical corridor. Monaca converts Appalachian ethane into polyethylene, one of the largest such complexes in North America, and stabilized production in 2024 after a difficult startup.
For ExxonMobil, the strategic logic is the clearest. Exxon already operates one of the largest chemicals businesses among oil majors, with a Gulf Coast footprint that includes its Baytown, Beaumont and Baton Rouge complexes. Acquiring Shell's Gulf Coast assets would add density to an already-integrated chain, letting Exxon spread overhead across more capacity and improve its position in linear alpha-olefins and polyethylene. Exxon's second-quarter 2026 results showed chemical products earnings improving on "North American feed advantage and performance chemical margins," with $307 million of earnings in the segment - a division that is profitable, unlike Shell's. Exxon is not buying Shell's chemicals to turn them around; it is buying them because it already knows how to run them at a profit.
For LyondellBasell, the logic is different and more defensive. LyondellBasell is a pure-play chemicals company without Shell's upstream cash engine, and it has been conducting its own portfolio surgery - completing the sale of select European olefins and polyolefins assets to AEQUITA in May 2026. Adding Shell's US assets would give LyondellBasell scale in exactly the markets where it is trying to concentrate, but it would also require capital that a company with a roughly $22 billion market capitalization may need to raise or finance through asset swaps. LyondellBasell's interest, if confirmed, signals that the deal's value is in consolidation, not rescue.
Other bidders could include private equity firms and Middle Eastern entities seeking to expand their Western presence, according to people briefed on the process. That roster would fit a broader pattern: Western oil majors are shrinking their chemicals books while state-backed and financial buyers expand theirs.
Cyclical Trough or Structural Exit? The Call
Here is the judgment this story turns on: Shell's chemicals sale is a structural reorientation executed at a cyclical trough - and the structural part is what matters.
The cyclical layer is real and ugly. Global chemicals margins have been compressed by weak demand, new Chinese capacity coming online, and elevated energy costs in Europe. LyondellBasell's own European divestment and Shell's Singapore sale - to a consortium controlled by Indonesia's PT Chandra Asri Pacific with Glencore holding a minority stake, completed April 1, 2025 - are both moves in the same wind. A buyer negotiating today knows Shell has been losing money and that the rebound, when it comes, may take years. That is why the $8 billion figure should be treated as an aspiration, not a forecast.
But the structural layer is what will outlast the cycle. Sawan's strategy is to concentrate Shell on oil, gas and biofuels businesses where it believes it holds a durable advantage, and to shrink capital employed in chemicals by 2030. This is not a tactical trim; it is a redefinition of what kind of company Shell wants to be. The evidence that this is structural, not cyclical, is that Shell is willing to sell advantaged assets - Monaca's shale ethane feedstock is a long-term competitive edge - rather than wait for margins to recover. Companies selling on cyclical timing hold their best assets and auction the weak ones. Shell appears prepared to sell the crown jewels too.
The counter-thesis is strong and deserves its due: Shell is selling at the bottom. Chemicals is a cyclical industry; margins mean-revert; and divesting loss-making capacity at the trough of the cycle is the classic value-destroying move that investors warn against. If the chemicals cycle turns in 2027 or 2028, Shell will have sold $8 billion of assets that could have been worth considerably more, and the "not the natural owner" framing will look like a rationalization for bad timing. The strongest version of this argument notes that Shell has already written down and restructured these assets - the losses are partly behind it - and that a patient owner with scale could capture the full rebound.
The answer to that counter-thesis is that Shell is not claiming it could never make money in chemicals. It is claiming that the capital would earn more somewhere else in the group. That is a hurdle-rate argument, and it survives a cyclical rebound: even if chemicals margins recover, Shell's deepwater and LNG projects may still clear a higher return bar. The falsifying signal is specific and observable: if Shell's chemicals segment posts positive adjusted earnings for four consecutive quarters while peer producers with comparable scale - Dow, LyondellBasell - continue to earn above their cost of capital, and if Shell simultaneously fails to deploy the sale proceeds into upstream projects yielding returns above the chemicals division's recovered returns, then the structural-exit thesis is wrong and the sale was a cyclical mistake. Watch the quarterly segment results and Shell's capital allocation disclosures.
Second-Order Consequences: The Re-Rating of Integration
The first-order story is simple: Shell sells, ExxonMobil or LyondellBasell buys, chemicals capacity changes hands. The second-order story is more consequential. For half a century, the integrated oil major model held that owning the molecule from wellhead to polymer made strategic sense - refineries and crackers shared feedstock, logistics and risk. Shell's exit, following similar moves across the sector, is a vote against that orthodoxy. It says integration is not a moat; scale and cost position are.
That re-rating has implications beyond Shell. Other majors holding chemicals assets - and there are several, including ExxonMobil's growing book and TotalEnergies' integrated chain - now face an implicit question from investors: why do you own this? If ExxonMobil acquires Shell's US chemicals, it will be making a concentrated bet that its operating model can extract profitability where Shell could not. That is a defensible bet, but it is a bet, and it will be measured quarter by quarter.
There is also a cross-ownership twist. Shell and ExxonMobil already operate a joint venture at Mossmoran in the United Kingdom. A deal that makes ExxonMobil the owner of Shell's former US assets while the two remain partners in Scotland would create a web of interdependence that antitrust regulators in Washington and Brussels will examine closely. The US Federal Trade Commission has shown little patience for consolidation that reduces the number of credible suppliers in specialty molecules, and linear alpha-olefins is a market where the buyer count is already small.
Who Benefits, Who Is Exposed
The beneficiaries are clear. ExxonMobil gains optionality to add scale in advantaged feedstock regions; LyondellBasell gains a path to consolidation if it can finance it; private equity and Middle Eastern buyers gain a foothold in Western chemicals at a depressed entry point. The exposed party is Shell's shareholders - but only if the sale is poorly executed. A rushed divestment at a cyclical low would crystallize the value destruction Sawan is trying to avoid. A disciplined, staged exit - asset by asset, with partnership structures where full sales are not priceable - would validate the strategy.
The employees and communities around Deer Park, Geismar, Norco and Monaca face a different kind of exposure. New owners bring new capital plans, and a private equity buyer in particular would carry a different cost discipline than an integrated major. That is a real social cost of the portfolio shift, even if the financial logic is sound.
What to Watch
The process will move through stages over the coming months. First, indications of interest from the named parties and any new bidders. Second, Shell's decision on whether to run a formal auction or pursue bilateral negotiations - the presence of ExxonMobil, a strategic buyer with the cash to act, makes a bilateral path plausible. Third, regulatory scrutiny, particularly if the final buyer is ExxonMobil or if a Middle Eastern state-backed entity bids for assets with defense-adjacent supply chains.
By time horizon: in the short term, expect volatility in Shell's share price around any announcement, with the stock likely to trade on the size of the proceeds rather than the strategic logic. In the medium term, the key metric is whether Shell actually reduces capital employed in chemicals and reinvests the proceeds at higher returns - the 2030 target is the scorecard. In the long term, the question is whether the chemicals assets, under new ownership, prove that scale was indeed the missing ingredient - or whether Shell sold into a trough and watched the cycle do the work it declined to wait for.
Scenarios: the base case is a staged sale of Gulf Coast assets to ExxonMobil or a consortium, with Monaca either partnered or sold separately at a later date, for a total closer to $6 billion to $7 billion than to the $8 billion headline. The upside case for Shell is a competitive auction that pulls in Middle Eastern capital and clears $8 billion or more. The downside case is a stalled process, with assets remaining on the books through the next cyclical upturn - the outcome that would make this entire strategy look like a mistake.
The closing judgment: Shell is not fleeing chemicals because they are unprofitable today; it is exiting because it has decided it would rather be a different company. Whether that is wisdom or bad timing will be decided not by the sale price, but by what Shell builds with the money.
Explore more exclusive insights at nextfin.ai.
